{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mikasi SG"],"funding":["Poliomyelitis Research Foundation","South African Research Chairs Initiative of the Department of Science and Innovation","Higher Education Department, next Generation of Programme","South African Research Chairs Initiative of the Department of Science and Innovation (DSI)","National Research Foundation","South African Medical Research Council","Department of Science and Technology, Republic of South Africa","Harry Crossley Foundation"],"pagination":["379"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8063366"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["Background
The Integrase (IN) strand transfer inhibitor (INSTI), Dolutegravir (DTG), has been given the green light to form part of first-line combination antiretroviral therapy (cART) by the World Health Organization (WHO). DTG containing regimens have shown a high genetic barrier against HIV-1 isolates carrying specific resistance mutations when compared with other class of regimens.Methods
We evaluated the HIV-1 CRF02_AG IN gene sequences from Cameroon for the presence of resistance-associated mutations (RAMs) against INSTIs and naturally occurring polymorphisms (NOPs), using study sequences (n = 20) and (n = 287) sequences data derived from HIV Los Alamos National Laboratory database. The possible impact of NOPs on protein structure caused by HIV-1 CRF02_AG variations w"],"journal":["BMC infectious diseases"],"pubmed_title":["Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations."],"pmcid":["PMC8063366"],"funding_grant_id":["17/49","64751","UID: 113547"],"pubmed_authors":["Isaacs D","Jacobs GB","Chitongo R","Mikasi SG","Cloete R","Ikomey GM"],"additional_accession":[]},"is_claimable":false,"name":"Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.","description":"Background
The Integrase (IN) strand transfer inhibitor (INSTI), Dolutegravir (DTG), has been given the green light to form part of first-line combination antiretroviral therapy (cART) by the World Health Organization (WHO). DTG containing regimens have shown a high genetic barrier against HIV-1 isolates carrying specific resistance mutations when compared with other class of regimens.Methods
We evaluated the HIV-1 CRF02_AG IN gene sequences from Cameroon for the presence of resistance-associated mutations (RAMs) against INSTIs and naturally occurring polymorphisms (NOPs), using study sequences (n = 20) and (n = 287) sequences data derived from HIV Los Alamos National Laboratory database. The possible impact of NOPs on protein structure caused by HIV-1 CRF02_AG variations w","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2025-04-22T15:49:02.784Z","creation":"2022-02-09T16:06:33.606Z"},"accession":"S-EPMC8063366","cross_references":{"pubmed":["33892628"],"doi":["10.1186/s12879-021-06059-x"]}}